List view / Grid view
Preclinical program of translational research to identify new target proteins...
19 June 2013 | By Sanofi
Preclinical program of translational research to identify new target proteins...
First and only agent to statistically significantly improve survival in…
5 February 2013 | By Sanofi
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen...
New data presented at American Society of Hematology Annual Meeting…
9 December 2012 | By Sanofi
New data presented at American Society of Hematology Annual Meeting show activity against disease and symptom alleviation...
American Society of Hematology, Atlanta, GA., 8-11 December, 2012...
3 December 2012 | By Sanofi
American Society of Hematology, Atlanta, GA., 8-11 December, 2012...
“We are pleased that CHMP has supported our ZALTRAP application..."
16 November 2012 | By Sanofi
“We are pleased that CHMP has supported our ZALTRAP application..."
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed…
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
Progress on Jevtana®, Zaltrap™ and JAK2 inhibitor featured...
16 May 2012 | By Sanofi
Progress on Jevtana®, Zaltrap™ and JAK2 inhibitor featured...
The FDA has granted Priority Review of the BLA for…
5 April 2012 | By Sanofi
The FDA has granted Priority Review of the BLA for the investigational agent Zaltrap®...
Sanofi announced new data for iniparib (BSI-201)...
6 June 2011 | By Sanofi
Sanofi announced new data for iniparib (BSI-201)...
Data will be presented at the ESMO World Congress on…
6 June 2011 | By Sanofi
Data will be presented at the ESMO World Congress on Gastrointestinal Cancer...
